Roche reported that in a clinical trial, Ocrevus, a treatment for multiple sclerosis, did not exhibit any better effects than the standard dose.
Roche’s attempt to increase the use of its best-selling medication has failed.
According to Roche, a late-stage study revealed that a dose two to three times greater than the typical 600 mg version did not demonstrate any extra benefit in delaying the progression of relapsing multiple sclerosis.
In the meantime, Ocrevus is Roche’s top-selling medication and a key factor in the company’s expansion. Sales are expected to reach approximately 7.59 billion USD in 2024.
